Results 51 to 60 of about 66,673 (183)
Clinical features of mastocytosis at pediatric patients
Vestnik Dermatologii i Venerologii, 2017 Mastocytosis is relevant to heterogeneous disease group characterized with redundant accumulation and proliferation of mast cells in tissues. The skin form of mastocytosis is mainly occurs in children.
D. V. Proshutinskaya, O. S. Makoveckaya
doaj +1 more source
Clinical and Translational Allergy, Volume 16, Issue 7, July 2026.ABSTRACT Background A variety of clinical signs and symptoms have been described in patients suspected of having mast cell activation syndrome (MCAS), however, symptom patterns and linked organ systems were not yet described. Methods This cross‐sectional online survey included adults with physician‐diagnosed self‐assessed or suspected MCAS between June
Annika Gutsche +13 more
wiley +1 more source
Cancer Nexus, Volume 2, Issue 3, July 2026.Graphical abstract illustrating the clinical course and treatment response. ABSTRACT Systemic mastocytosis (SM) is a clonal hematologic neoplasm driven by activating KIT mutations, particularly D816V. Indolent SM typically follows a stable course, progression to higher‐burden subtypes is uncommon.
Homeniuk Anna +5 more
wiley +1 more source
Health Science Reports, Volume 9, Issue 7, July 2026.ABSTRACT Background and Aims Hymenoptera venom hypersensitivity is a potentially life‐threatening condition that may affect up to 7.5% of adults worldwide and can result in systemic allergic reactions ranging from generalized cutaneous symptoms to severe anaphylaxis.
Bharat Kumar +3 more
wiley +1 more source
Role of Cysteinyl Leukotrienes in Food Allergy and Anaphylaxis: A Potential Therapeutic Target
Allergy, EarlyView.
Adrienn Weingärtner, Thomas Eiwegger
wiley +1 more source
European S2k guidelines on management of autoimmune blistering diseases in children and adolescents
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1137-1161, July 2026.Autoimmune blistering disorders (AIBDs) in children are rare, challenging to diagnose and treat and often require immunosuppressants. Until now, no paediatric care guidelines existed. The EADV Task Force for AIBDs has developed the consensus‐based recommendations, enabling physicians to adopt a uniform, tailored treatment strategy to improve outcomes ...
A. Nanda +31 more
wiley +1 more source
Pediatric Allergy and Immunology, Volume 37, Issue 7, July 2026.Breakthrough reactions in Pediatric chemotherapeutic desensitization: outcomes and associated risk factors. Abstract Background Rapid drug desensitization (RDD) enables the safe reintroduction of chemotherapeutic agents in patients with hypersensitivity reactions (HSRs).
Pathitta Doradee +6 more
wiley +1 more source
Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States
ChemMedChem, Volume 21, Issue 11, 15 June 2026.Kinetic profiling of 172 compounds across KIT conformations—including D816V—reveals kinetic fingerprints that predict efficacy, selectivity, resistance, and inhibitors’ ability to stabilize key regulatory elements. Far from a secondary metric, binding kinetics provide mechanistic insights beyond affinity, offering a powerful framework for rational drug
Ana Corrionero +7 more
wiley +1 more source
Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
Haematologica, 2018 Mastocytosis is a term used to denote a group of rare diseases characterized by an abnormal accumulation of neoplastic mast cells in various tissues and organs.
Michel Arock +10 more
doaj +1 more source